Archives
- 2018-07
- 2018-10
- 2018-11
- 2019-04
- 2019-05
- 2019-06
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-07
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
-
While a number of studies have helped elucidate the principl
2020-01-23
While a number of studies have helped elucidate the principles of target amino group specificity, UBL selectivity, and Ub Nogo-66 (1-40) synthesis specificity [3], [4], [9], [10], [14], [19], [20], [23], [24], [33], [34], [37], [38], [39], [40], [41], the role of the canonical E2-RING interface in
-
Next we evaluated neutralization of Jc Jc N A
2020-01-23
Next, we evaluated neutralization of Jc1, Jc1-N534A, Jc1-ΔHVR1 and Jc1-ΔHVR1-N534A by sera from individuals chronically infected with HCV GT1 and GT2 (Fig. 4A-C). Like the results of neutralization with monoclonal BCECF-AM mg and CD81-LEL (Fig. 3), the sera poorly neutralized Jc1. Neutralization was
-
br Agonist binding ETA activation
2020-01-22
Agonist binding ETA activation is promoted by binding of the endogenous peptidergic agonists to their orthosteric binding site on the receptor. ET1 and ET2 (Trp6-Leu7-ET1) bind with equal high affinity to ETA, whereas the third endogenous isopeptide ET3 (Thr2-Phe4-Thr5-Tyr6-Lys7-Tyr14-ET1) binds
-
In our xenograft study Fig Fig we
2020-01-22
In our xenograft study (Fig. 7, Fig. 8), we observed that DYD acts very similarly to progesterone; the initial faster tumor growth in the PGRMC1-transfected MCF7 tumor was not significant compared with that with progesterone, in Spadin to the greater tumor growth observed with norethisterone. This
-
A French cohort study reported
2020-01-22
A French cohort study reported that micronized progesterone or didrogesterone used with oral or percutaneous estradiol showed no increase or decrease in the risk of breast cancer compared to synthetic progestins for at least 4 years of treatment [22] and even after 8 years [23]. Although the results
-
E protein expressed in a plasmid encoding codon optimized
2020-01-22
E1 protein expressed in a plasmid encoding codon-optimized canine oral papillomavirus (COPV) led to therapeutic immunization of COPV-infected Beagle dogs [25], [26], which was better than that achieved with plasmids encoding E2 or E7 COPV. Moreover, E1 and E2 from cottontail rabbit papillomavirus (C
-
br Experimental section br Results and
2020-01-22
Experimental section Results and discussion Conclusions In conclusion, we have presented an autocatalytic recycling amplification electrochemical biosensing platform for simple, rapid and ultrasensitive detection of MTase activity by combining methylation-sensitive restriction endonuclease
-
Our data indicate that the
2020-01-22
Our data indicate that the ability of these promiscuous kinases to bind chemically diverse inhibitors is defined by the hydrophobic pocket formed by the activation loop, which is only accessible in the DFG-Asp-out conformation. Inhibitors do not artificially induce the DFG-Asp-out conformation as wa
-
Here we also took attempt to evaluate the CYP mediated
2020-01-22
Here we also took attempt to evaluate the CYP mediated inhibition potential of S. chirata and its biomarker ursolic Protease Inhibitor Library on pooled RLM by CYP-CO complex assay. We observed that S. chirata extract and ursolic acid showed less enzyme inhibition than known inhibitor (ketoconazole
-
During the course of our research on mGlu PAMs the
2020-01-22
During the course of our research on mGlu PAMs,, the hydroxyacetophenone scaffold was found to possess dual mGlu PAM and CysLT1 antagonism activity, presumably as orthosteric antagonist (). There is currently an increasing interest in drug discovery to explore multitarget drugs or polypharmacology
-
br Acknowledgements We thank Jeffrey
2020-01-22
Acknowledgements We thank Jeffrey D. Konowalchuk and John Sony Robbins for their technical assistance. This work was supported by Natural Sciences and Engineering Research Council of Canada (NSERC) grants to DRB (RGPIN-2013-355303) and MB (RGPIN-2014-96395). AMR was supported by NSERC Vanier Doct
-
br Materials and methods br Results and discussion br Conclu
2020-01-22
Materials and methods Results and discussion Conclusions Acknowledgments This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean government (MEST) (No. 2011-0030635) and the MarineBio Research Program (NRF-C1ABA001-2011-0018561). The Fonta
-
Given the molecular pharmacology and in
2020-01-22
Given the molecular pharmacology and in vitro metabolism data, we proceeded to evaluate the in vivo pharmacokinetics of . Mice (=3) were subsequently administered a subcutaneous dose (5mg/kg) with intermittent plasma collections to measure systemic levels of (). Compound achieved a maximum plasma
-
To study systemic potential of the selected
2020-01-22
To study systemic potential of the selected compounds as EP1 receptor antagonist, they were evaluated with regard to the sulprostane-induced increase of intravesical bladder pressure in rats. Some of the analogs, 13 and 15–17, which were selected on the basis of their in vitro EP1 receptor affinity,
-
br Methods br Results br Discussion
2020-01-22
Methods Results Discussion With this study, we provided evidence that acriflavine can interfere with EMT and UPR, two well-described pathways associated with cancer aggressiveness. And, because drug resistance is also clearly associated with the mesenchymal state [36], blocking of the epith
15050 records 827/1004 page Previous Next First page 上5页 826827828829830 下5页 Last page